Rani Therapeutics (NASDAQ:RANI) Given New $5.00 Price Target at Canaccord Genuity Group
Rani Therapeutics (NASDAQ:RANI – Get Free Report) had its target price decreased by investment analysts at Canaccord Genuity Group from $9.00 to $5.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. A number of other equities analysts have also issued reports on the company. Weiss […]
1 Apr 17:18 · The Cerbat Gem